IP Library Granted Patent US 8,435,204
Granted Patent B2
US 8,435,204 · App. 12/444,581 · Granted May 7, 2013

Cerebrospinal fluid purification system

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,435,204
App. No.
12/444,581
Granted
May 7, 2013
Kind
B2
Abstract

The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF) by removing target compounds from CSF. A multilumen flow path allows exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents.

Claims (17)

1. A method for ameliorating a symptom of cerebral vasospasm in a patient, said method comprising:

selecting a patient having the symptom of cerebral vasospasm;

removing cerebrospinal fluid from a first location in a lumbar cerebrospinal fluid space of the patient;

removing at least one of erythrocytes, hemoglobin, oxyhemoglobin and endothelin from the removed cerebrospinal fluid, thereby conditioning the cerebrospinal fluid at a flow rate; and

returning the conditioned cerebrospinal fluid to the patient at a second location in a cervical cerebrospinal fluid space or ventricle of the patient, wherein the cerebrospinal fluid is returned to the patient at substantially the same flow rate at which it is removed;

wherein the removing and returning steps are performed concurrently using a catheter having a first lumen with a first proximal port at the first location and a second lumen having a second distal port at the second location during at least a portion of a conditioning treatment.

2. A method as in claim 1 , wherein the flow rate is in a range from 0.04 ml/min to 30 ml/min.

3. A method as in claim 2 , wherein a volume of cerebrospinal fluid removed from the patient never exceeds 40 ml.

4. A method as in claim 1 , wherein the second location is in the cervical cerebrospinal fluid space.

5. A method as in claim 1 , wherein the second location is in the ventricle of a brain.

6. A method as in claim 1 , wherein flow directions of removing and returning cerebrospinal fluid are periodically reversed so that CSF is returned to the first location and removed from the second location during a portion of the treatment.

7. A method as in claim 6 , wherein the flow reversal is a pulse to dislodge debris from removal or return ports.

8. A method as in claim 1 , further comprising mixing the conditioned cerebrospinal fluid with endogenous cerebrospinal fluid as the conditioned cerebrospinal fluid is returned to the cerebrospinal fluid space.

9. A method as in claim 8 , wherein mixing comprises inducing a turbulent flow as the conditioned cerebrospinal fluid is returned.

10. A method as in claim 1 , further comprising the step of isolating the at least one of erythrocytes, hemoglobin, oxyhemoglobin and endothelin.

11. A method as in claim 1 , wherein conditioning comprises one or more separation processes selected from the group consisting of biospecific affinity, immunoaffinity, cationic exchange, anionic exchange, hydrophobicity and size exclusion.

12. A method as in claim 1 , wherein the conditioning step is performed externally to the patient's body.

Assignments (8)
RELEASE OF PATENT SECURITY AGREEMENT - REEL/FRAME 054795/0607, SUPPLEMENTAL PATENT SECURITY AGREEMENT - REAL/FRAME 056240/0147 AND ASSIGNMENT ID: 885388 Recorded Oct 1, 2025
From: TEXAS CAPITAL BANK, AS AGENT
To: MINNETRONIX MEDICAL, INC.
Reel/Frame 073434/0838 →
PARTIAL RELEASE OF PATENT SECURITY AGREEMENT - REEL 054795 FRAME 0607; AND REEL 056240 FRAME 0147 Recorded Jun 10, 2025
From: TEXAS CAPITAL BANK, AS ADMINISTRATIVE AGENT
To: MINNETRONIX, INC.; MINNETRONIX NEURO, INC. (F/K/A NEUROFLUIDICS, INC.)
Reel/Frame 071588/0015 →
ASSIGNMENT OF SECURITY INTEREST IN PATENT COLLATERAL RECORDED ON REEL 054795 FRAME 0607 AND SUPPLEMENTAL PATENT SECURITY AGREEMENT RECORDED ON REEL 056240 FRAME 0147 Recorded Mar 13, 2025
From: FIRST HORIZON BANK
To: TEXAS CAPITAL BANK, AS SUCCESSOR AGENT
Reel/Frame 073460/0969 →
SECURITY INTEREST Recorded Jan 4, 2021
From: MINNETRONIX MEDICAL, INC.; MINNETRONIX NEURO, INC.
To: FIRST HORIZON BANK, AS ADMINISTRATIVE AGENT
Reel/Frame 054795/0607 →
RELEASE OF SECURITY INTEREST Recorded Dec 31, 2020
From: MINNESOTA BANK & TRUST
To: MINNETRONIX MEDICAL, INC.; MINNETRONIX NEURO, INC.
Reel/Frame 054788/0122 →
SECURITY INTEREST Recorded Dec 16, 2014
From: MINNETRONIX, INC.
To: MINNESOTA BANK & TRUST
Reel/Frame 034518/0602 →
SECURITY INTEREST Recorded Dec 16, 2014
From: NEUROFLUIDICS, INC.
To: MINNESOTA BANK & TRUST
Reel/Frame 034518/0931 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2010
From: LAD, SHIVANAND; MOBLEY, WILLIAM C.; NIKOLICH, KAROLY; SAUL, THOMAS
To: NEUROFLUIDICS, INC.
Reel/Frame 024692/0636 →